bluebird bio Inc (BLUE)
0.3636
-0.01
(-3.91%)
USD |
NASDAQ |
Nov 14, 16:00
0.3636
0.00 (0.00%)
After-Hours: 20:00
bluebird bio Research and Development Expense (Quarterly): 25.16M for June 30, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 25.16M |
| March 31, 2024 | 25.07M |
| December 31, 2023 | 33.77M |
| September 30, 2023 | 45.46M |
| June 30, 2023 | 31.45M |
| March 31, 2023 | 41.59M |
| December 31, 2022 | 5.575M |
| September 30, 2022 | 53.15M |
| June 30, 2022 | 63.84M |
| March 31, 2022 | 77.88M |
| December 31, 2021 | 79.38M |
| September 30, 2021 | 73.68M |
| June 30, 2021 | 84.64M |
| March 31, 2021 | 82.84M |
| December 31, 2020 | -131.55M |
| September 30, 2020 | 140.43M |
| June 30, 2020 | 156.31M |
| March 31, 2020 | 154.12M |
| December 31, 2019 | -93.47M |
| September 30, 2019 | 151.41M |
| June 30, 2019 | 146.54M |
| March 31, 2019 | 122.64M |
| December 31, 2018 | 119.72M |
| September 30, 2018 | 116.74M |
| June 30, 2018 | 115.01M |
| Date | Value |
|---|---|
| March 31, 2018 | 97.11M |
| December 31, 2017 | 92.58M |
| September 30, 2017 | 61.54M |
| June 30, 2017 | 63.89M |
| March 31, 2017 | 55.03M |
| December 31, 2016 | 57.13M |
| September 30, 2016 | 63.97M |
| June 30, 2016 | 41.76M |
| March 31, 2016 | 41.91M |
| December 31, 2015 | 35.66M |
| September 30, 2015 | 30.40M |
| June 30, 2015 | 44.27M |
| March 31, 2015 | 23.72M |
| December 31, 2014 | 20.53M |
| September 30, 2014 | 16.65M |
| June 30, 2014 | 13.93M |
| March 31, 2014 | 11.46M |
| December 31, 2013 | 9.765M |
| September 30, 2013 | 8.706M |
| June 30, 2013 | 7.247M |
| March 31, 2013 | 5.284M |
| December 31, 2012 | 6.497M |
| September 30, 2012 | 3.501M |
| June 30, 2012 | 3.354M |
| March 31, 2012 | 3.858M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
-131.55M
Minimum
Dec 2020
156.31M
Maximum
Jun 2020
49.96M
Average
53.15M
Median
Sep 2022
Research and Development Expense (Quarterly) Benchmarks
| Perspective Therapeutics Inc | 9.275M |
| Protalix BioTherapeutics Inc | 2.961M |
| Predictive Oncology Inc | -- |
| Spectral AI Inc | -- |
| AIM ImmunoTech Inc | 1.145M |